AstraZeneca’s Enhertu granted fourth FDA breakthrough therapy designation
AstraZeneca has received the US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for Enhertu (trastuzumab deruxtecan) to treat a type of breast cancer. The drug has